BACKGROUND: Peritoneal membrane damage induced by peritoneal dialysis (PD) is largely associated with epithelial-to-mesenchymal transition (EMT) of mesothelial cells (MCs), which is believed to be a result mainly of the glucose degradation products (GDPs) present in PD solutions. OBJECTIVES: This study investigated the impact of bicarbonate-buffered, low-GDP PD solution (BicaVera: Fresenius Medical Care, Bad Homburg, Germany) on EMT of MCs in vitro and ex vivo. IN VITRO STUDIES: Omentum-derived MCs were incubated with lactate-buffered standard PD fluid or BicaVera fluid diluted 1:1 with culture medium. Ex vivo studies: From 31 patients randomly distributed to either standard or BicaVera solution and followed for 24 months, effluents were collected every 6 months for determination of EMT markers in effluent MCs. RESULTS: Culturing of MCs with standard fluid in vitro resulted in morphology change to a non-epithelioid shape, with downregulation of E-cadherin (indicative of EMT) and strong induction of vascular endothelial growth factor (VEGF) expression. By contrast, in vitro exposure of MCs to bicarbonate/low-GDP solution had less impact on both EMT parameters. Ex vivo studies partially confirmed the foregoing results. The BicaVera group, with a higher prevalence of the non-epithelioid MC phenotype at baseline (for unknown reasons), showed a clear and significant trend to gain and maintain an epithelioid phenotype at medium- and longer-term and to show fewer fibrogenic characteristics. By contrast, the standard solution group demonstrated a progressive and significantly higher presence of the non-epithelioid phenotype. Compared with effluent MCs having an epithelioid phenotype, MCs with non-epithelioid morphology showed significantly lower levels of E-cadherin and greater levels of fibronectin and VEGF. In comparing the BicaVera and standard solution groups, MCs from the standard solution group showed significantly higher secretion of interleukin 8 and lower secretion of collagen I, but no differences in the levels of other EMT-associated molecules, including fibronectin, VEGF, E-cadherin, and transforming growth factor β1. Peritonitis incidence was similar in both groups. Functionally, the use of BicaVera fluid was associated with higher transport of small molecules and lower ultrafiltration capacity. CONCLUSIONS: Effluent MCs grown ex vivo from patients treated with bicarbonate/low-GDP BicaVera fluid showed a trend to acquire an epithelial phenotype, with lower production of proinflammatory cytokines and chemokines (such as interleukin 8) than was seen with MCs from patients treated with a lactate-buffered standard PD solution.
BACKGROUND: Peritoneal membrane damage induced by peritoneal dialysis (PD) is largely associated with epithelial-to-mesenchymal transition (EMT) of mesothelial cells (MCs), which is believed to be a result mainly of the glucose degradation products (GDPs) present in PD solutions. OBJECTIVES: This study investigated the impact of bicarbonate-buffered, low-GDP PD solution (BicaVera: Fresenius Medical Care, Bad Homburg, Germany) on EMT of MCs in vitro and ex vivo. IN VITRO STUDIES: Omentum-derived MCs were incubated with lactate-buffered standard PD fluid or BicaVera fluid diluted 1:1 with culture medium. Ex vivo studies: From 31 patients randomly distributed to either standard or BicaVera solution and followed for 24 months, effluents were collected every 6 months for determination of EMT markers in effluent MCs. RESULTS: Culturing of MCs with standard fluid in vitro resulted in morphology change to a non-epithelioid shape, with downregulation of E-cadherin (indicative of EMT) and strong induction of vascular endothelial growth factor (VEGF) expression. By contrast, in vitro exposure of MCs to bicarbonate/low-GDP solution had less impact on both EMT parameters. Ex vivo studies partially confirmed the foregoing results. The BicaVera group, with a higher prevalence of the non-epithelioid MC phenotype at baseline (for unknown reasons), showed a clear and significant trend to gain and maintain an epithelioid phenotype at medium- and longer-term and to show fewer fibrogenic characteristics. By contrast, the standard solution group demonstrated a progressive and significantly higher presence of the non-epithelioid phenotype. Compared with effluent MCs having an epithelioid phenotype, MCs with non-epithelioid morphology showed significantly lower levels of E-cadherin and greater levels of fibronectin and VEGF. In comparing the BicaVera and standard solution groups, MCs from the standard solution group showed significantly higher secretion of interleukin 8 and lower secretion of collagen I, but no differences in the levels of other EMT-associated molecules, including fibronectin, VEGF, E-cadherin, and transforming growth factor β1. Peritonitis incidence was similar in both groups. Functionally, the use of BicaVera fluid was associated with higher transport of small molecules and lower ultrafiltration capacity. CONCLUSIONS: Effluent MCs grown ex vivo from patients treated with bicarbonate/low-GDP BicaVera fluid showed a trend to acquire an epithelial phenotype, with lower production of proinflammatory cytokines and chemokines (such as interleukin 8) than was seen with MCs from patients treated with a lactate-buffered standard PD solution.
Authors: John D Williams; Kathrine J Craig; Nicholas Topley; Christopher Von Ruhland; Maureen Fallon; Geoffrey R Newman; Ruth K Mackenzie; Geraint T Williams Journal: J Am Soc Nephrol Date: 2002-02 Impact factor: 10.121
Authors: María Yáñez-Mó; Enrique Lara-Pezzi; Rafael Selgas; Marta Ramírez-Huesca; Carmen Domínguez-Jiménez; José A Jiménez-Heffernan; Abelardo Aguilera; José A Sánchez-Tomero; M Auxiliadora Bajo; Vincente Alvarez; M Angeles Castro; Gloria del Peso; Antonio Cirujeda; Carlos Gamallo; Francisco Sánchez-Madrid; Manuel López-Cabrera Journal: N Engl J Med Date: 2003-01-30 Impact factor: 91.245
Authors: G Sansone; A Cirugeda; M A Bajo; G del Peso; J A Sánchez Tomero; L Alegre; Y Hernández; N Polanco; P Delgado Mallén; C Soares; C Hevia; R Selgas Journal: Nefrologia Date: 2004 Impact factor: 2.033
Authors: Luiz S Aroeira; Abelardo Aguilera; Rafael Selgas; Marta Ramírez-Huesca; M Luisa Pérez-Lozano; Antonio Cirugeda; M Auxiliadora Bajo; Gloria del Peso; José A Sánchez-Tomero; José A Jiménez-Heffernan; Manuel López-Cabrera Journal: Am J Kidney Dis Date: 2005-11 Impact factor: 8.860
Authors: Siska Mortier; An S De Vriese; Rachel M McLoughlin; Nicholas Topley; Thomas P Schaub; Jutta Passlick-Deetjen; Norbert H Lameire Journal: J Am Soc Nephrol Date: 2003-05 Impact factor: 10.121
Authors: Janusz Witowski; Justyna Wisniewska; Katarzyna Korybalska; Thorsten O Bender; Andrzej Breborowicz; Gerhard M Gahl; Ulrich Frei; Jutta Passlick-Deetjen; Achim Jörres Journal: J Am Soc Nephrol Date: 2001-11 Impact factor: 10.121
Authors: Seychelle Yohanna; Ali M A Alkatheeri; Scott K Brimble; Brendan McCormick; Arthur Iansavitchous; Peter G Blake; Arsh K Jain Journal: Clin J Am Soc Nephrol Date: 2015-06-05 Impact factor: 8.237
Authors: Gloria del Peso; José Antonio Jiménez-Heffernan; Rafael Selgas; César Remón; Marta Ossorio; Antonio Fernández-Perpén; José Antonio Sánchez-Tomero; Antonio Cirugeda; Erika de Sousa; Pilar Sandoval; Raquel Díaz; Manuel López-Cabrera; María Auxiliadora Bajo Journal: Perit Dial Int Date: 2015-10-16 Impact factor: 1.756
Authors: Yeoungjee Cho; David W Johnson; David A Vesey; Carmel M Hawley; Margaret Clarke; Nicholas Topley Journal: Perit Dial Int Date: 2014-04-07 Impact factor: 1.756
Authors: Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Fiona G Brown; Neil Boudville; Kym M Bannister; Philip A Clayton; David W Johnson Journal: Clin J Am Soc Nephrol Date: 2013-08-15 Impact factor: 8.237
Authors: María Luisa Pérez-Lozano; Pilar Sandoval; Angela Rynne-Vidal; Abelardo Aguilera; José Antonio Jiménez-Heffernan; Patricia Albar-Vizcaíno; Pedro L Majano; José Antonio Sánchez-Tomero; Rafael Selgas; Manuel López-Cabrera Journal: PLoS One Date: 2013-04-09 Impact factor: 3.240
Authors: Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho Journal: Cochrane Database Syst Rev Date: 2018-10-26